Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema

What are the safety, tolerability, and effects associated with intravitreal vamikibart (anti–interleukin 6 antibody) in uveitic macular edema (UME)?In this open-label, multiple-ascending-dose, phase 1, nonrandomized clinical trial, 37 patients with UME secondary to noninfectious uveitis (NIU) received intravitreal vamikibart. Across all doses (0.25 mg, 1 mg, 2.5 mg) from baseline to 12 weeks, vamikibart was tolerated and associated with improved best-corrected visual acuity and central subfield thickness.This evidence supports short-term safety and tolerability, as well as visual acuity and macular central subfield thickness improvement, of intravitreal vamikibart in cases of UME secondary to NIU.

Corresponding Author: Marina Mesquida, MD, PhD, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland (marina.mesquida@roche.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.